Diagnostic tools for charcot-marie-tooth disease

Patent metadata

Field	Value
Publication number	US-9494605-B2
Application number	US-201013510700-A
Country	US
Kind code	B2
Filing date	Nov 19, 2010
Priority date	Nov 20, 2009
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

The present invention relates in particular to methods of detecting predisposition to or diagnosis and/or prognosis of Charcot-Marie-Tooth (CMT) and related disorders. More specifically, the invention relates to development, validation and application of new biomarkers, which can be used for detecting the presence or risk of CMT disease and related disorders. In particular, the present invention relates to metabolite, lipid, carbohydrate and proteinaceous biomarkers that can be measured in biological body fluids and easily available extracts of biopsies, which can be used to aid in the detection, prediction of drug treatment and follow up of this treatment of neurodegenerative disorders, including CMT disease. The present invention also relates to methods for identification of CMT disease subtypes, assessing the responsiveness to the treatments and the efficacy of treatments in subjects having CMT or a related disorder.

First claim

The invention claimed is:

1. A method of detecting and treating a presence or risk of Charcot-Marie-Tooth type 1A disease in a mammal, the method comprising:
(i) obtaining a plasma or serum sample from the mammal,
(ii) extracting cholesterol from said plasma or serum sample with heptanes,
(iii) oxidizing the extracted cholesterol by a Jones oxidation, wherein free cholesterol is oxidized into cholest-4-en-3,6-dione,
(iv) quantifying the amount of cholest-4-en-3,6-dione by HPLC/UV analysis which corresponds to the plasma or serum amount of free cholesterol,
(v) comparing said amount of free cholesterol with an age-matched plasma or serum control sample or reference value,
(vi) detecting the presence or risk of Charcot-Marie-Tooth type 1A disease in said mammal if said amount of free cholesterol is reduced as compared to the control sample or value of step (v), and
(vii) treating the mammal identified as having or being at risk of having Charcot-Marie-Tooth type 1A disease according to step (vi) by administering a drug or drug combination that treats Charcot-Marie-Tooth type 1A disease.

2. The method of claim 1 , wherein the amount of total cholesterol is measured.

3. The method of claim 1 , further comprising:
(a) simultaneously or sequentially quantifying the amount of at least one second biomarker from a fluid biological sample from said mammal, wherein said at least one second biomarker is selected from the group consisting of low-density lipoprotein cholesterol, alanine, α-aminobutyric acid, citrulline, cystine, glutamine, hydroxyproline, lysine, methionine, proline, threonine, tryptophan, tyrosine, thyroxine (T4), testosterone, iron, leukotriene B4, adrenaline, dopamine and serotonin; and
(b) comparing the value obtained in (a) with a reference or control value from the mammal.

4. The method of claim 3 , wherein said at least one second biomarker is:
alanine;
thyroxine, tryptophan and hydroxyproline;
hydroxyproline;
thyroxine and tryptophan;
thyroxine and serotonin;
thyroxine and hydroxyproline;
thyroxine; or
serotonin.

5. The method of claim 1 , wherein at least one additional diagnostic test for Charcot-Marie-Tooth type 1A disease is performed, wherein said additional diagnostic test is selected from the group consisting of detection of a nucleic acid marker, detection of a proteinous marker, a physiological test, a neurophysiological test, a genetic test, a behavioral test, an electrophysiological test, a clinical test, and a phenotypical test.

Assignees

• Cohen Daniel
• Chumakov Ilya
• Nabirochkin Serguei
• Pharnext

Inventors

• Cohen Daniel
• Chumakov Ilya
• Guerassimenko Oxana
• Nabirochkin Serguei

Classifications

• G01N33/6896

  Neurological disorders, e.g. Alzheimer's disease · CPC title

• G01N2800/285

  Demyelinating diseases; Multipel sclerosis · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• A61K31/047

  having two or more hydroxy groups, e.g. sorbitol · CPC title

• G01N33/78

  Thyroid gland hormones {, e.g. T3, T4, TBH, TBG or their receptors} · CPC title